| 1 |
Argollo MC, Kotze PG, Spinelli A, et al.The impact of biologics in surgical outcomes in ulcerative colitis[J]. Best Pract Res Clin Gastroenterol, 2018, 32-33: 79-87.
|
| 2 |
Neurath MF, Travis SP.Mucosal healing in inflammatory bowel diseases: a systematic review[J]. Gut, 2012, 61(10): 1619-1635.
|
| 3 |
Ma C, Battat R, Jairath V, et al.Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease[J]. Curr Treat Options Gastroenterol, , 2019, 17(1): 127-145.
|
| 4 |
Eberhardson M, Hedin CRH, Carlson M, et al.Towards improved control of inflammatory bowel disease[J]. Scand J Immunol, 2019, 89(3): e12745.
|
| 5 |
Colombel JF, Sandborn WJ, Reinisch W, et al.Infliximab, azathioprine, or combination therapy for Crohn′s disease[J]. N Engl J Med, 2010, 362(15): 1383-1395.
|
| 6 |
Rutgeerts P, Van Assche G, Sandborn WJ, et al.Adalimumab induces and maintains mucosal healing in patients with Crohn′s disease: data from the EXTEND trial[J]. Gastroenterology, 2012, 142(5): 1102-1111.e2.
|
| 7 |
Vuitton L, Marteau P, Sandborn WJ, et al.IOIBD technical review on endoscopic indices for Crohn′s disease clinical trials[J]. Gut, 2016, 65(9): 1447-1455.
|
| 8 |
Lega S, Dubinsky MC.What Are the Targets of Inflammatory Bowel Disease Management[J]. Inflamm Bowel Dis, 2018, 24(8): 1670-1675.
|
| 9 |
Colombel JF, Rutgeerts P, Reinisch W, et al.Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis[J]. Gastroenterology, 2011, 141(4): 1194-1201.
|
| 10 |
D′Haens G, Noman M, Baert F, et al.Endoscopic healing after infliximab treatment for Crohn′s disease provides a longer time to relapse[J]. Gastroenterology, 2002, 122: A618.
|
| 11 |
D′Haens G, Baert F, van Assche G, et al.Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn′s disease: an open randomised trial[J]. Lancet, 2008, 371(9613): 660-667.
|
| 12 |
Baert FJ, Moortgat L, Van Assche G, et al.Mucosal Healing Predicts Sustained Clinical Remission in Early Crohn′s Disease[J]. Gastroenterology, 2008, 134(4 Suppl 1): A640.
|
| 13 |
Libier L, Collins M, Koriche D, et al.Evaluation and Long-Term Benefit of Mucosal Healing in Crohn′s Disease Patients Treated With Infliximab[J]. Gastroenterology, 2015, 148(4 Suppl 1): S450.
|
| 14 |
Sandborn WJ, Colombel JF, Reinisch W, et al.Infliximab induces and maintains mucosal healing in ulcerative colitis patients: the ACT trials[J]. Am J Gastroenterol, 2005, 100: S310.
|
| 15 |
Rutgeerts P, Diamond RH, Bala M, et al.Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn′s disease[J]. Gastrointest Endosc, 2006, 63(3): 433-442.
|
| 16 |
Schnitzler F, Fidder H, Ferrante M, et al.Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn′s disease[J]. Inflamm Bowel Dis, 2009, 15(9): 1295-1301.
|
| 17 |
Froslie KF, Jahnsen J, Moum BA, et al.Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort[J]. Gastroenterology, 2007, 133(2): 412-422.
|
| 18 |
Laharie D, Filippi J, Roblin X, et al.Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience[J]. Aliment Pharmacol Ther, 2013, 37(10): 998-1004.
|
| 19 |
Molander P, Sipponen T, Kemppainen H, et al.Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD[J]. J Crohns Colitis, 2013, 7(9): 730-735.
|
| 20 |
Juncadella A, Papamichael K, Vaughn BP, et al.Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease[J]. Dig Dis Sci, 2018, 63(11): 3067-3073.
|
| 21 |
Dignass A, Stoynov S, Dorofeyev AE, et al.Once versus three times daily dosing of oral budesonide for active Crohn′s disease: a double-blind, double-dummy, randomised trial[J]. J Crohns Colitis, 2014, 8(9): 970-980.
|
| 22 |
Colombel JF, Reinisch W, Mantzaris GJ, et al.Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn′s disease-a SONIC post hoc analysis[J]. Aliment Pharmacol Ther, 2015, 41(8): 734-746.
|
| 23 |
Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al.Clinical implications of mucosal healing for the management of IBD[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(1): 15-29.
|
| 24 |
Hanauer SB, Sandborn WJ, Dallaire C, et al.Delayed-release oral mesalamine 4.8 g/day(800 mg tablets)compared to 2.4 g/day(400 mg tablets)for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial[J]. Can J Gastroenterol, 2007, 21(12): 827-834.
|
| 25 |
Hanauer SB, Sandborn WJ, Kornbluth A, et al.Delayed-release oral mesalamine at 4.8 g/day(800 mg tablet)for the treatment of moderately active ulcerative colitis: the ASCEND II trial[J]. Am J Gastroenterol, 2005, 100(11): 2478-2485.
|
| 26 |
Meucci G, Fasoli R, Saibeni S, et al.Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study[J]. Inflamm Bowel Dis, 2012, 18(6): 1006-1010.
|
| 27 |
Casellas F, Barreiro de Acosta M, Iglesias M, et al.Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease[J]. Eur J Gastroenterol Hepatol, 2012, 24: 762-769.
|